SIRP alpha Lysate | SIRPA lysate

Human SIRP alpha HEK293 Overexpression Lysate

Cat. Num. AAA8119642

• Applications: Western Blot
• Synonyms: SIRP alpha; Human SIRP alpha HEK293 Overexpression Lysate; Human SIRP alphaV2 HEK293 Cell Lysate (WB positive control); Human BIT Overexpression Lysate; Human CD172A Overexpression Lysate; Human MFR Overexpression Lysate; Human MYD-1 Overexpression Lysate; Human P84 Overexpression Lysate; Human PTPNS1 Overexpression Lysate; Human SHPS1 Overexpression Lysate; Human SIRP Overexpression Lysate; Human SIRP alpha Overexpression Lysate; signal-regulatory protein alpha; SIRPA lysate

• Host: HEK293 Cells
• Form/Format: Modified RIPA Lysis Buffer: 50 mM Tris-HCl pH7.4, 150 mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% SDS, 1% Sodium deoxycholate, 1mM PMSF.; 1 X Sample Buffer (1 X modified RIPA buffer+1 X SDS loading buffer).

• Applicable Applications for SIRPA lysate: Western Blot (WB)
• Application Notes: Western blot (WB): Use at an assay dependent dilution.
• Species: Human
• Sequence Information: A DNA sequence encoding the human SIRP alphaV2 (AAH38510.1)(Met1-Arg369) was expressed with a polyhistidine tag at the C-terminus.
• Preparation Method: Cell lysate was prepared by homogenization in ice-cold modified RIPA Lysis Buffer with cocktail of protease inhibitors (Sigma). Cell debris was removed by centrifugation. Protein concentration was determined by Bradford assay (protein assay, Microplate Standard assay). The cell lysate was boiled for 5 min in 1 x SDS loading buffer (50mM Tris-HCl pH6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% b-mercaptoethanol, and lyophilized.
• Recommend Usage: 1. Centrifuge the tube for a few seconds and ensure the pellet at the bottom of the tube.; 2. Re-dissolve the pellet using 200uL pure water and boil for 2-5 min.; 3. Store the lyophilized cell lysate at 4 degree C. After re-dissolution, recommend to aliquot it into smaller quantities and store at -80 degree C.
• Preparation and Storage: Store at 4 degree C for up to twelve months from date of receipt. After re-dissolution, aliquot and store at -80 degree C for up to twelve months. Avoid repeated freeze-thaw cycles.

Related Product Information for SIRPA lysate

Description: This Human SIRP alpha overexpression lysate was created in HEK293 Cells and intented for use as a Western blot (WB) positive control. Purification of SIRP alpha protein from the overexpression lysate was verified.

Background: HEK293 Cell Human SIRP alphaV2 transfected/overexpressed for Western blot (WB) positive control. The whole cell lysate is provided in 1X Sample Buffer (1X modified RIPA buffer+1X SDS loading buffer).
Tyrosine-protein phosphatase non-receptor type substrate 1, also known as SHP substrate 1, Inhibitory receptor SHPS-1, Brain Ig-like molecule with tyrosine-based activation motifs, Macrophage fusion receptor, CD172 antigen-like family member A, SIRPA and CD172a, is a single-pass type I membrane protein which contains two Ig-like C1-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. SIRPA is ubiquitously expressed. It is highly expressed in brain and detected at lower levels in heart, placenta, lung, testis, ovary, colon, liver, small intestine, prostate, spleen, kidney, skeletal muscle and pancreas. It is also detected on myeloid cells, but not T-cells. SIRPA is an immunoglobulin-like cell surface receptor for CD47. SIRPA acts as docking protein and induces translocation of PTPN6, PTPN11 and other binding partners from the cytosol to the plasma membrane. SIRPA supports adhesion of cerebellar neurons, neurite outgrowth and glial cell attachment. It may play a key role in intracellular signaling during synaptogenesis and in synaptic function. SIRPA is involved in the negative regulation of receptor tyrosine kinase-coupled cellular responses induced by cell adhesion, growth factors or insulin. It mediates negative regulation of phagocytosis, mast cell activation and dendritic cell activation.

Product Categories/Family for SIRPA lysate

Cancer Drug Targets

References

Timms JF. et al., 1999, Curr Biol. 9: 927-30. Stofega MR. et al., 2000, J Biol Chem. 275: 28222-9. Liu T. et al., 2005, J Proteome Res. 4: 2070-80. Wolf-Yadlin A. et al., 2007, Proc Natl Acad Sci. 104: 5860-5.